Value-Based Clinical Pathways in the World of Reference-Priced Medicare Part B Drugs
As health care shifts to a focus on value-based outcomes, there is a need for all stakeholders to deliver on both clinical and financial outcomes. This means that clinical pathways must take into account the financial aspects of treatments. READ MORE
Senate Democrats Introduce Bill To Allow Government To Block Drug Price Rises
(Reuters) Dec 13, 2018 - Four Democratic U.S. senators introduced a bill on Thursday that would allow the government to block drug price increases that it decides are unjustified. READ ARTICLE